Sartorius Stedim Biotech acquires Cellca

Sartorius Stedim Biotech (SSB), an international supplier to the pharma and biotech industries, has acquired the Laupheim (Germany) based Cellca GmbH, which offers cell line and process development services for large-scale protein production of biologics in mammalian (CHO) cells.
 
Founded in 2005, Cellca with around 30 employees generated sales revenue of approximately 6 million euros in 2014. Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities.
 
Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development. SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.
 
Reinhard Vogt, member of the Sartorius Stedim Biotech executive committee for marketing and sales, said, “Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics.”
 
Hugo de Wit, the Managing Director of Cellca, added, “Due to its global presence and high reputation, Sartorius Stedim Biotech is an ideal partner for Cellca. We now have a strong base to further expand and develop our business internationally.”